IMMUNOTECH-B (06978) announced its annual results for the period ended December 31, 2025. The group recorded other income of 20.507 million yuan, a decrease of 39.31% year-on-year. Research and development expenses amounted to 133 million yuan, down 13.89% compared to the previous year. The loss attributable to the company's owners was 231 million yuan, an increase of 23.47% year-on-year. The loss per share was 0.42 yuan.

EAL® is a broad-spectrum anti-tumor cellular immunotherapy product with a clinical application track record of over ten years in cancer treatment. EAL® is a preparation developed by activating and expanding T-cells initially harvested from a patient's own peripheral blood using a proprietary method. The product's primary active component is CD8+ cytotoxic T-cells, with CD3 molecules serving as their cell surface marker.

As of the date of this announcement, the group has completed the enrollment of 430 target subjects for its Phase II clinical trial. In March 2025, EAL® received acceptance for its conditional New Drug Application (NDA). Subsequently, EAL® was included in China's priority review and approval list. As of the announcement date, the conditional NDA application for the group's core candidate product, EAL®, is currently under review by the Center for Drug Evaluation of the National Medical Products Administration.